Validation of Messenger Ribonucleic Acid Markers Differentiating Among Human ARDS Subgroups in an Ovine Model of ARDS Phenotypes

Wildi K, Hyslop K, Millar J, Livingstone S, Passmore MR, Bouquet M, Wilson E, LiBassi G, Fraser JF, Suen JY. Frontiers in Medicine 2022 9 DOI: doi.org/10.3389/fmed.2022.961336

Background: The discovery of biological subphenotypes in acute respiratory distress syndrome (ARDS) might offer a new approach to ARDS in general and possibly targeted treatment, but little is known about the underlying biology yet. To validate our recently described ovine ARDS phenotypes model, we compared a subset of messenger ribonucleic acid (mRNA) markers in leukocytes as reported before to display differential expression between human ARDS subphenotypes to the expression in lung tissue in our ovine ARDS phenotypes model (phenotype 1 (Ph1): hypoinflammatory; phenotype 2 (Ph2): hyperinflammatory).

Previous
Previous

Incidence of death or disability at 6 months after ECMO in Australia: a prospective, multicentre, registry-embedded cohort study

Next
Next

Transcriptomic profiling of cardiac tissues from SARS-CoV-2 patients identifies DNA damage